All In Biotech

Drug Trial Radar · NCT07798375

A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration

A Multicenter, Randomized, Quadruple-Masked, Active-Controlled Phase 2b Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of VIS-101 Intravitreal Injection in Treatment- Naïve Participants With Neovascular Age-Related Macular Degeneration

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 244 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

244

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Jul 2028

Study completion Dec 2028

Sponsor

Sponsor type
Industry
Collaborators
Visara, Inc.
First posted
Sep 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy, safety, durability, and pharmacokinetics of VIS-101 administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD)

Conditions

  • Neovascular Age Related Macular Degeneration(nAMD)

Interventions

  • VIS-101 6.0mg Low concentrationBiological

    VIS-101 will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.

  • VIS-101 6.0mg High concentrationBiological

    VIS-101 will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.

  • VIS-101 9.0mg High concentrationBiological

    VIS-101 will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.

  • Aflibercept (Eylea)Biological

    Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks (Q8W).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in BCVA from baseline to Week 36Time frame: From Baseline through Week 36

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.